KOSDAQ - Delayed Quote KRW

Optipharm.CO.,LTD (153710.KQ)

5,170.00
-40.00
(-0.77%)
At close: May 16 at 3:30:30 PM GMT+9
Loading Chart for 153710.KQ
  • Previous Close 5,210.00
  • Open 5,140.00
  • Bid 5,100.00 x --
  • Ask 5,110.00 x --
  • Day's Range 5,030.00 - 5,210.00
  • 52 Week Range 4,400.00 - 7,640.00
  • Volume 18,491
  • Avg. Volume 8,244
  • Market Cap (intraday) 75.844B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and changed its name to Optipharm.CO.,LTD in 2012. Optipharm.CO.,LTD was founded in 2000 and is based in Cheongju, South Korea.

www.optipharm.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 153710.KQ

View More

Performance Overview: 153710.KQ

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

153710.KQ
11.30%
KOSPI Composite Index (^KS11)
9.48%

1-Year Return

153710.KQ
24.53%
KOSPI Composite Index (^KS11)
4.58%

3-Year Return

153710.KQ
45.75%
KOSPI Composite Index (^KS11)
1.17%

5-Year Return

153710.KQ
49.06%
KOSPI Composite Index (^KS11)
36.30%

Compare To: 153710.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 153710.KQ

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    75.84B

  • Enterprise Value

    72.62B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.85

  • Price/Book (mrq)

    2.77

  • Enterprise Value/Revenue

    3.70

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.00%

  • Return on Assets (ttm)

    -3.71%

  • Return on Equity (ttm)

    -8.98%

  • Revenue (ttm)

    19.64B

  • Net Income Avi to Common (ttm)

    -2.36B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.23B

  • Total Debt/Equity (mrq)

    40.27%

  • Levered Free Cash Flow (ttm)

    -1.01B

Research Analysis: 153710.KQ

View More

Company Insights: 153710.KQ

Research Reports: 153710.KQ

View More

People Also Watch